BHONSLE SUNIL (See Remarks) purchased 221.3% of their position (300K shares) of TITAN PHARMACEUTICALS INC on the open market
Open‑market purchase worth $75.0K — a major conviction buy. The strongest form of insider conviction signal.
P · 1 purchase
Filed: 9/25/2018ACC: 0001144204-18-050781
DirectorOfficer· See Remarks
Since Sep 2018
+600K
Net shares
Net buyer
$75.0K
Total acquired
1
Open market trades
1B · 0S
2
Total transactions
600K acquired
Non-Derivative Transactions1
Common Stock
Direct
Shares
+300K
Price / share
$0.25
Trade value
$75K
% of position
221.3%
9/21/2018
135.58K→435.58K
Total
Net shares
+300K
Net value
$75K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 9/21/2018 | P · Purchase | +300K | $0.25 | $75K | 221.3% | 135.58K | 435.58K |
| Total | +300K | $75K | ||||||
Derivative Transactions1
Warrants
Direct
Converts to
common stock
300K shares
Shares
+300K
Strike price
0.25
Held after
300K
Exercisable
—
9/21/2018
| Security | Converts To | Date | Type | Shares | Strike Price | Exercisable | Held After |
|---|---|---|---|---|---|---|---|
| Warrants Direct | common stock300K shares | 9/21/2018 | A · Award | +300K | 0.25 | — | 300K |
Non-Derivative Holdings (Post-Transaction)1
Common Stock
IndirectShares owned54.68K
Total
54.68K indirect54.68K
| Security Title | Shares Owned | Ownership Type |
|---|---|---|
| Common Stock | 54.68K | Indirect |
| Total | 54.68K | 54.68K indirect |
Derivative Holdings (Post-Transaction)0
No derivative holdings reported